Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers

Sieroń, Aleksander; Namysłowski, Grzegorz; Misiołek, Maciej; Adamek, Mariusz; Kawczyk‐Krupka, Aleksandra

doi:10.1007/s004050100347

Cited by 59 publications

(75 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, McGillis and Fein 15 and Rivard and Ozog 16 have also applied ALA for 30 minutes before illumination and exposition to light for 10 minutes in 3 fractions. In most of the previous studies the light sources used were lasers at 635 nm, Kübler et al, 17 Fan et al, 18 Kubler et al, 19 Sieron et al, 20 Sieroń et al, 21 Tsai et al, 22 Chen et al, 23 Lin et al, 24 and 585 nm, Franco, 25 Shafirstein et al 26 But, because of their bulkiness and high cost, we have chosen LED at 420 nm, like McGillis and Fein, 15 Rivard and Ozog, 16 Ericson et al, 27 Jerjes et al, 28 as it is cheaper, convenient, safe and easy to use in the treatment of OL and OLP. In the present study, 12 OL lesions were treated with 5-ALA mediated PDT, among which 2 (16.7%) showed complete response, 8 (66.67%) partial response and 2 (16.7%) no response.…”

Section: Discussionmentioning

confidence: 99%

Photodynamic Therapy – A Non-invasive Treatment Modality for Precancerous Lesions

et al. 2016

View full text Add to dashboard Cite

Introduction: Oral premalignant lesions are conditions having high potential tendency for transformation into malignancy. The use of a conservative and effective treatment modality is one of the best strategies for cancer prevention. Photodynamic therapy (PDT) is a noninvasive method for topical and selective treatment of oral precancerous lesions. The present study was taken up to determine the efficacy of PDT in oral precancerous lesions. Methods: The study consisted 13 patients with 24 oral leukoplakia (OL) lesions and 8 with 20 oral lichen planus (OLP) lesions, divided into control and study groups. These lesions were affecting various intraoral sites, the buccal mucosa being the most common site followed by tongue and gingiva. The treatment regimen of PDT included 98% 5-aminolevulinic acid (5-ALA) which is topical applied and irradiated with light emitting diode (LED) of 420 nm wavelengths at several sessions. Results: In OL 16.6% of cases showed complete response, 66.6% partial response and 16.6% no response of the lesions to the treatment. In OLP 80% and 20% of the lesions showed partial and no response respectively. The differences with control groups for OL + OLP were found to be significant (P < 0.001). Conclusion: Based on the results of the present study, we can conclude that PDT appears to be a feasible alternative to conventional therapy for oral premalignant lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Photodynamic Therapy – A Non-invasive Treatment Modality for Precancerous Lesions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Sieron treated five patients with larynx and hypopharynx carcinomas using ALA-PDT. All five patients achieved only a partial response (31). Transient liver function abnormalities occurred in all patients.…”

Section: Early Stage Head and Neck Cancer: Ala-mediated Pdtmentioning

confidence: 95%

“…Transient liver function abnormalities occurred in all patients. Due to the limited depth of accumulation of ALA and the limited penetration of 635-nm light, tumors greater than 2 mm depth are not consistently cured (29)(30)(31).…”

Section: Early Stage Head and Neck Cancer: Ala-mediated Pdtmentioning

confidence: 99%

Photodynamic Therapy of Head and Neck Cancers

Biel

2010

Methods in Molecular Biology

108

View full text Add to dashboard Cite

Over 1,500 patients have been treated with PDT using Photofrin, HPD, ALA, or Foscan for head and neck cancers. These patients include a mixture of presentations including primary, recurrent, and metastatic lesions. The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma. Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers. Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT. Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment. Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up. Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck. It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.

show abstract

“…In the case of the gastrointestinal (GI) tract, the most intensively studied applications of PDT include Barrett's oesophagus and various levels of dysplasia, as well as early oesophageal cancer [144]. Such diseases involve superficial and frequently large mucosal areas, which are readily accessible to light piloted to the treatment site by means of optical fibres.…”

Section: Clinical Indications For Pdtmentioning

confidence: 99%

Basic and Clinical Aspects of Photodynamic Therapy

Rapozzi

Jori

2014

Resistance to Targeted Anti-Cancer Therapeutics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) was originally developed for the treatment of solid tumors by the concerted action of a tumor-localizing agent, named as the photosensitizer, molecular oxygen and visible light source. The photoinduced cytotxic species are mainly represented by singlet oxygen ( 1 O 2 ), even though the formation of NO has been observed in selected situations. Optimal results are generally obtained by using porphyrins and their tetrapyrrolic analogues as the photodynamic agents, since these compounds display an intense absorbance of the red spectra wavelengths, which are endowed with a particularly deep penetration into most biological tissues. While several porphyrins exhibit an intrinsic preferential affinity for malignant tissues, the selectivity of the tumor localization can be significantly enhanced by pre-binding the photosensitizer with a targeting agent, such as an antibody or a vehicle (e.g., glycoproteins, peptides, oligonucleotide aptamers, growth factors, lipoproteins) directed against antigens or receptors which are specifically present at the surface of tumor cells. Recently, novel perspectives have been opened by the association of the photosensitizer with nanoparticles, which can be made to be multifunctional, thereby allowing the simultaneous delivery of photoactivatable moieties acting by different mechanisms, as well as of phototherapeutic and photodiagnostic agents. The chemical structure of the photosensitizer and the nature of the possible carrier have important consequences with regards to the distribution of the photosensitizer among different compartments of the tumor tissue, such as neoplastic cells, blood vessels or the non-vascular stroma, as well as its localization in different subcellular sites; these would obviously affect the mechanism of photoinduced tumor damage, modulating the competition between necrosis, apoptosis and autophagia, the importance of photoinduced hypoxia, and the balance between enhancement of the immune response and immunosuppression. So far, about 250 randomized clinical trials have been officially reported for 4 V. Rapozzi and G. Jori PDT of tumors, and essentially all types of solid tumors with the exception of melanotic melanoma have been found to be positively responsive to the photodynamic treatment. Thus, PDT is currently considered as a reasonable option for the treatment of a variety of malignant lesions for curative or palliative purposes by using either external or endoscopic irradiation approaches via non-coherent or laser light sources.

show abstract

Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers

Cited by 59 publications

References 8 publications

Photodynamic Therapy – A Non-invasive Treatment Modality for Precancerous Lesions

Photodynamic Therapy – A Non-invasive Treatment Modality for Precancerous Lesions

Photodynamic Therapy of Head and Neck Cancers

Basic and Clinical Aspects of Photodynamic Therapy

Contact Info

Product

Resources

About